Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04367740 · ClinicalTrials.gov registry record
ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 6,313
- Enrollment target
NCT04367740 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 6,313 participants.
The verdict
NCT04367740 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 6,313 participants
- Enrollment target
Study Summary
Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
Interventions
- DIAGNOSTIC_TEST To assess for development of IgG antibodies against SARS-CoV2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,313 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2022-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04367740
The ClinicalTrials.gov registry entry for NCT04367740 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which To assess for development of IgG antibodies against SARS-CoV2 is the first listed.
NCT04367740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04367740 about?
NCT04367740 is a clinical study titled "ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19". Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
What is the current status of trial NCT04367740?
This trial is currently completed. The enrollment target is 6,313 participants. The study started on 2020-04-28. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT04367740?
The interventions under investigation include: To assess for development of IgG antibodies against SARS-CoV2 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04367740?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.